The Baker Institute paper isn’t a rigorous economic or statistical paper, to put it lightly.
Their conclusions appear to be drawn by simply eyeballing charts and making observations. They don’t provide statistical analysis or reasoning for their conclusions. They don’t address the issues arising in regards to OTC trading and NYMEX traded contracts. They mention that the Commodity Futures Modernization Act made it easier for non-commercial entities to trade various types of swaps in the OTC markets, but then instead focus on only reported NYMEX data. One of the biggest problems, in my eyes, is the fact that they acknowledge that much of the increase in open interest/positions came in the form of spread trading. By definition, a spread trade is a market neutral position - for every dollar purchased, a dollar is sold short. The mechanism by which an increase in spreading could result in an upward spike in prices isn’t even hinted at by the authors. Overall, the paper seems to cherry pick data and draw conclusions without really providing much to back up their assertions.
I suggest this page for a critical review of the Baker Institute paper.
So I didn’t misread it? That’s good to know, at any rate. I’ll admit (again) that this is not my field, so anything that I do get right is good. And thank you for addressing my actual point.
I would point out that the authors repeatedly represent the report as a “brief” showing correlations and trends, rather than a rigorous analysis. So, to use “lack of rigor” as a (the, actually) primary criticism is disingenuous, at best. And they do say that there is a more thorough report due out later this season – from what I can tell, it’s supposed to cover the same material, but with more rigor. We’ll see, I suppose…
What I gathered from reading Dr. Pirrong’s critique (your link) is that he’s got an axe to grind…most likely, it seems, similar to a health insurance corporation trashing attempts at health reform. But that doesn’t mean the Baker analysis isn’t flawed – or even fundamentally flawed. Looking for a bit more information, I prefer this analysis as being more fair (same conclusion concerning speculators). Quoting a bit from that entry:
That sums it up pretty damn well.
But you’ve mentioned two other things: (1) spreads and (2) NYMEX vs. OTC. About (1), Pirrong derides the Baker report:
It seems to me, possibly in my ignorance, that it’s obvious (as you point out) that spreaders don’t exert a large effect on prices – by definition. So what? There’s no claim that I can see that spreaders affect price. So I’m not sure where he (or you) score a resounding argumentative win with that point, or whether it’s a red herring to begin with. As to (2), it seems eminently reasonable to assume that NYMEX trading exhibits similar characteristics to OTC trading; if speculation is a problem in NYMEX, it would also likely be a problem in OTC. The issue, AIUI, is that no data is available for OTC trading, making it utterly impossible to analyze it in the first place.
Honestly, again, I don’t have the expertise to adequately judge this stuff (and picking up the required amount of expertise anytime soon isn’t likely). I hope this wasn’t too much of a thread hijack, and I can only hope I’ve done the topic some justice.